Efe, CumaliTascilar, KorayGerussi, AlessioBolis, FrancescaLammert, CraigEbik, BeratStattermayer, Albert FriedrichCengiz, MustafaGokce, Dilara TuranCristoferi, LauraPeralta, MirtaMassoumi, HatefMontes, PedroCerda, EiraRigamonti, CristinaYapali, SunaAdali, GupseCaliskan, Ali RizaBalaban, YaseminEren, FatihEskazan, TugceBarutcu, SezginLytvyak, EllinaZazueta, Godolfino MirandaKayhan, Meral AkdoganHeurgue-Berlot, AlexandraDe Martin, EleonoraYavuz, AhmetBiyik, MuratNarro, Graciela CastroDuman, SerkanHernandez, NeliaGatselis, Nikolaos K.Aguirre, JonathanIdilman, RamazanSilva, MarceloMendizabal, ManuelAtay, KadriGuzelbulut, FatihDhanasekaran, RenumathyMontano-Loza, Aldo J.Dalekos, George N.Ridruejo, EzequielInvernizzi, PietroWahlin, Staffan2024-10-072024-10-072022-10-010896-8411https://doi.org/10.1016/j.jaut.2022.102906https://www.sciencedirect.com/science/article/pii/S0896841122001147?via%3Dihubhttps://hdl.handle.net/11452/45960Background: Data regarding outcome of Coronavirus disease 2019 (COVID-19) in vaccinated patients with autoimmune hepatitis (AIH) are lacking. We evaluated the outcome of COVID-19 in AIH patients who received at least one dose of Pfizer- BioNTech (BNT162b2), Moderna (mRNA-1273) or AstraZeneca (ChAdOx1-S) vaccine. Patients and methods: We performed a retrospective study on AIH patients with COVID-19. The outcomes of AIH patients who had acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection after at least one dose of COVID-19 vaccine were compared to unvaccinated patients with AIH. COVID-19 outcome was classified according to clinical state during the disease course as: (i) no hospitalization, (ii) hospitalization without oxygen supplementation, (iii) hospitalization with oxygen supplementation by nasal cannula or mask, (iv) intensive care unit (ICU) admission with non-invasive mechanical ventilation, (v) ICU admission with invasive mechanical ventilation or (vi) death, and data was analyzed using ordinal logistic regression. Results: We included 413 (258 unvaccinated and 155 vaccinated) patients (81%, female) with a median age of 52 (range: 17-85) years at COVID-19 diagnosis. The rates of hospitalization were (36.4% vs. 14.2%), need for any supplemental oxygen (29.5% vs. 9%) and mortality (7% vs. 0.6%) in unvaccinated and vaccinated AIH patients with COVID-19. Having received at least one dose of SARS-CoV-2 vaccine was associated with a significantly lower risk of worse COVID-19 severity, after adjusting for age, sex, comorbidities and presence of cirrhosis (adjusted odds ratio [aOR] 0.18, 95% confidence interval [CI], 0.10-0.31). Overall, vaccination against SARSCoV-2 was associated with a significantly lower risk of mortality from COVID-19 (aOR 0.20, 95% CI 0.11-0.35). Conclusions: SARS-CoV-2 vaccination significantly reduced the risk of COVID-19 severity and mortality in patients with AIH.eninfo:eu-repo/semantics/openAccessVaccinesLiver failureBreakthrough infectionImmunosuppressionVaccineAutoimmunityImmunologyArticle00091171380000513210.1016/j.jaut.2022.102906